Fibrodysplasia Ossificans Progressiva | CHOP Research Institute
 

Fibrodysplasia Ossificans Progressiva

Published on
Jan 31, 2022
Identified by CHOP researchers, palovarotene is the first drug approved (in Canada) for fibrodysplasia ossificans progressiva, a severe bone disease.
Published on
Jul 23, 2021
This week’s In the News features new study on measuring vision changes in patients with neurofibromatosis type 1, and other research highlights.

Biomedical research in the Pacifici Laboratory spans three decades and has explored mechanisms of skeletal development and growth in fetal and postnatal life.

Published on
Jul 12, 2019
Many parents working in private sector are turning to Medicaid and CHIP for children’s healthcare coverage. This story and more In the News.

Dr. Pacifici's biomedical research spans three decades and has explored mechanisms of skeletal development and growth in fetal and postnatal life. Specifically, his focus has been on identifying the cellular and molecular mechanisms that regulate the differentiation of progenitor cells and permit assembly of distinct skeletal structures, and on aberrations of these mechanisms in pediatric skeletal disorders.

E-mail:
pacificim [at] chop.edu
Published on
Apr 15, 2016
This week’s stories have elements that sound like fiction, but all are real, new scientific and medical findings: A condition that turns the body’s soft tissues into bone has new hope for a future treatment. Genetic superheroes walk among us, and they may not even know it. And pediatricians may have a tool to double their success in helping their patients’ parents quit smoking.
Published on
Oct 8, 2014
As rare pediatric diseases go, Fibrodysplasia Ossificans Progressiva (FOP) is about as rare and debilitating as they come, affecting roughly one in two million people around the world.